J.P. Morgan: A market leader in pharma M&A
Track record: J.P. Morgan was lead financial counsel on the biggest pharma deal of 2019, advising Celgene on its $74 billion acquisition by Bristol-Myers Squibb. It had a busy year besides this; it advised The Medicines Company on its $9.7 billion purchase by Novartis, and was one of several banks advising GE Biopharma on its $21.4 billion acquisition by Danaher.
Team & differentiation: The healthcare team at J.P. Morgan is well-equipped to handle the size and complexity of deals in the sector, not to mention the regulatory hurdles. The bank has few peers when it comes to regularly handling high-value, market-shaping matters. Steven Frank and Mike Gaito are the key contacts for healthcare and pharmaceutical work.